Bioventus has filed for an initial public stock offering, according to The News & Observer.
Here are five points:
1. The company aims to raise up to $150 million through the IPO.
2. The company intends to use the funds to "pay off promissory notes and other debt that total $60 million among other things," according to the report.
3. Bioventus, a spin-off of Smith & Nephew formed in 2012, develops orthobiologic solutions for bone fusion and osteoarthritis.
4. The company's full-year revenue increased from $242.9 million in 2014 to $253.7 million in 2015; however, its net loss in 2015 totaled $34.1 million.
5. If Bioventus moves forward with the IPO, it will trade under the ticker symbol "BIOV" on Nasdaq.